Latest / Bloomberg Law / Bloomberg Law Brief: Allergan Patents Invalidated (Audio)
Transcript
- 0:00Speaker 1: Well, now it's time for our Bloomberg Law Report. Let's
- 0:03Speaker 1: get to the legal stories we're watching this morning with
- 0:05Speaker 1: Steve Podusk in the Bloomberg Washington news room. When the U. S.
- 0:10Speaker 1: Supreme Court rules on a case challenging American Express companies
- 0:14Speaker 1: merchant rules, it could shape how antitrust violations will be
- 0:18Speaker 1: judged in complex markets like healthcare or credit cards. Companies
- 0:22Speaker 1: that want to introduce new digital currencies into the marketplace
- 0:24Speaker 1: may have to brace for scrutiny from a new source.
- 0:27Speaker 1: The Commodity Futures Trading Commission and Verizon Communications will pay
- 0:31Speaker 1: seventeen point seven million dollars to resolve FCC and Department
- 0:35Speaker 1: of Justice investigations into whether it violated the rules of
- 0:38Speaker 1: a program that subsidizes broadband in schools and libraries. Bloomberg
- 0:43Speaker 1: Law everything you need, all on one legal research platform,
- 0:47Speaker 1: including guidance analysis and Bloomberg Market Intelligence. Find out more
- 0:51Speaker 1: at Bloomberg Law dot com. All right, thanks Steve. Now,
- 0:55Speaker 1: in other legal news, let's take a look at a
- 0:57Speaker 1: recent setback for drugmaker allergy And after a federal judge
- 1:01Speaker 1: ruled its use of an Indian tribe to protect patents
- 1:04Speaker 1: for the drug re stasis did not hold up in court.
- 1:08Speaker 1: Here with more in this story is Bloomberg Law host
- 1:10Speaker 1: Joam Grosso and Greg Sture speaking with Rutgers University Law
- 1:13Speaker 1: School professor Michael Carry and Bloomberg Intelligence senior litigation analyst
- 1:19Speaker 1: Owed Gersbacker. Oh tell us about Judge Bryson's decision on
- 1:24Speaker 1: the patents. Okay, so there's really two decisions that came down. Um,
- 1:29Speaker 1: one on the patents, invalidating all of them, so that
- 1:32Speaker 1: really clears the way for generics, and the other was
- 1:36Speaker 1: the decision to actually join the tribe to the lawsuit.
- 1:39Speaker 1: Could you explain what the decision was based on. The
- 1:42Speaker 1: patents were invalidated for um what we call obviousness in
- 1:46Speaker 1: patent law, and that just means that the judge found that,
- 1:50Speaker 1: prior to alegan filing these patent applications that eventually became patents,
- 1:56Speaker 1: the the invention had already been um made or disc
- 2:00Speaker 1: it or written about in different pieces of literature. Mike
- 2:04Speaker 1: tell us about the other decision, Uh, so, um that
- 2:09Speaker 1: he could have stopped. I guess with that one decision
- 2:11Speaker 1: that Ode was just talking about invalidating the patents, but
- 2:14Speaker 1: he also wrote something separate that talked about what he
- 2:17Speaker 1: called a ploy to transfer the patents to a Native
- 2:22Speaker 1: American trap. Tell us a little bit about that issue,
- 2:24Speaker 1: if you would. So that question was whether or not
- 2:26Speaker 1: aller Gun's motion would be granted to join a party,
- 2:30Speaker 1: to join the tribe to the lawsuit. At the end
- 2:32Speaker 1: of the day, the court said yes, because it wasn't
- 2:35Speaker 1: willing to take the chance that by not joining the
- 2:38Speaker 1: tribe eventually the decision could be thrown out if the
- 2:41Speaker 1: tribe really did play a role, a valid role in
- 2:44Speaker 1: this transaction. So the court was really being conservative in
- 2:47Speaker 1: saying there's a chance that the tribe could play a role,
- 2:51Speaker 1: so I will allow them to join the case. But
- 2:54Speaker 1: in doing that, to judge was as clear as I
- 2:57Speaker 1: have ever seen in a court opinion that is basically
- 3:00Speaker 1: a sham transaction, and there were tons of language that
- 3:03Speaker 1: made that clear. So, Mike, why would Allergan want to
- 3:07Speaker 1: transfer the patent to the st regious tribe? The primary
- 3:12Speaker 1: reason is that it allows them to make an argument
- 3:15Speaker 1: that they are now immune from having their patents challenged.
- 3:19Speaker 1: Sovereign immunity is a doctrine that goes back century. But
- 3:22Speaker 1: the point here is that Allergan was trying to transfer
- 3:26Speaker 1: the patent to the Native American tribe so that the
- 3:30Speaker 1: tribe would be immune. So if generics were challenging the
- 3:33Speaker 1: patents at the patent office, then they can say you're
- 3:36Speaker 1: out of law. The game's over because we are immune.
- 3:40Speaker 1: As Rutgers University Law School professor Michael Kerrier and Bloomberg
- 3:44Speaker 1: Intelligence Senior litigation analyst Ode Gersbacker speaking with Bloomberg's June
- 3:49Speaker 1: Grosso and Greg Store. You can listen to Bloomberg Law
- 3:52Speaker 1: weekdays at one pm Wall Street Time here on Bloomberg Radio,
- 3:56Speaker 1: and find more legal news at Bloomberg Law dot com.
- 3:58Speaker 1: Attorneys will find accept in a legal research and business
- 4:01Speaker 1: development tools there as well. Visit Bloomberg Law dot com
- 4:05Speaker 1: for more information.